4D Molecular Therapeutics, Inc. 10-Q filing
Filed 2025-08-11 · Report date 2025-06-30 · 2025
Filing metadata
- Accession number
- 0000950170-25-106244
- Form type
- 10-Q
- CIK
- 0001650648
- Primary document
- https://www.sec.gov/Archives/edgar/data/1650648/000095017025106244/fdmt-20250630.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for 4D Molecular Therapeutics, Inc..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Revenue | $29,000 | - | - |
| Operating Income | $-113.1M | - | - |
| Net Income | $-102.6M | - | - |
| Eps Basic | -1.84 | - | - |
| Eps Diluted | -1.84 | - | - |
| Cash And Equivalents | $77.2M | - | - |
| Total Assets | $473.6M | - | - |
| Total Liabilities | $52.7M | - | - |
| Shareholders Equity | $420.9M | - | - |
| Operating Cash Flow | $-91.1M | - | - |
| Capital Expenditures | $697,000 | - | - |